Get Permission Parasramani, Tahiliani, Deshmukh, Dhoot, and Barkate: Adult-onset acne: An expert consensus


Introduction

Acne is a pleomorphic disorder that can manifest at any time during life but is most commonly seen between the ages of 12 to 24, which estimates of 85% of population affected. It is among the most common dermatological conditions worldwide, with an estimated 650 million people affected.1, 2

Despite being considered as a disease of adolescent age group, recently it has been observed that the incidence and prevalence of adult patients with acne is on the rise.3, 4 Various authors has reported that the incidence of acne in patients of age group between 26 – 44 years is increasing. Perkins et al in their study reported that the incidence of acne in adult females is in the range of 12%–22%.5 Similarly Poli F et al concluded that in 41% patients acne persists in their adulthood.6 In the same study authors reported that in 78% of the females there is worsening of acne during premenstrual period.6 Goulden V et al in their study involving more than 700 people older than 25 years concluded that facial acne were reported by 12% of women and 3% of men.7

Despite this increase in incidence of adult acne, guidelines for management of these patients are lacking. Hence there are multiple apprehensions in the mind of dermatologist while managing such patients regarding which investigations to be done, which treatment regime is best suited for that patient, etc.

With this background, it was decided to develop consensus recommendations for diagnosis and management acne in adult patients in India.

Materials and Methods

The consensus document was developed using a modified Delphi method by a panel of subject experts. A multidisciplinary panel of experts was selected according to their clinical experience, their interest in the field as reflected by their international publications, and further, on their experience in generating guidelines. In order to develop the clinical statements for the consensus process, an electronic search of the PubMed database was performed. A thorough literature search was conducted to identify relevant articles written in English using keywords for adult acne management that were paired with terms such as diagnosis, hirsutism, female acne, late onset acne, treatment, isotretinoin, hormonal therapy in acne, retinoids and hyperandrogenism. The final results of the literature searches were distributed among the panel members, including electronic full-text versions. Experts were asked to review the articles identified during the literature searches for evidence gaps and areas of ambiguity for managing adult acne to assist with the development of clinical statements. Panel members were asked to complete two Delphi surveys one for diagnosis and another for management. Each survey was followed by a meeting (face to face), during which results were presented and statements were discussed.

The statements were categorized as follows:

  1. Consensus: Statements achieving a mean score of 7.00 or higher and having no more than one outlier.

  2. Near consensus: Statements achieving a mean score of 6.50 or higher and having no more than two outliers.

  3. No consensus: Statements that did not meet the criteria of consensus or near consensus.

After each round, statements with a near or no consensus were discussed to determine whether they should be refined and added to the following Delphi survey or omitted completely. This methodology did not require the ethics committee approval.

Results and Discussion

Following recommendations were made in the Delphi rounds.

Laboratory Investigations

In the presence of other clinical signs of hyperandrogenism, all the panel members suggested plasma concentrations of free and total testosterone, S-DHEA, Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and, in some cases, when suspecting PCOS, transvaginal ultrasound for visualization of the ovaries. These investigations should always be performed in the follicular phase, preferably between the first and fifth day of the menstrual cycle and the collection should be done in the morning, between 8 and 10 am. In this way, the hormonal variations of the menstrual cycle interfere less with blood analysis.

In suspected PCOS, the following criteria should be checked: presence of menstrual alterations (amenorrhea or oligomenorrhea), clinical and/or biochemical and/or hyperandrogenism, as well as ultrasonographic changes (presence of 12 or more follicles with 2 and 9 mm of diameter or increase in ovarian volume > 10cm3). Figure 1 presents a scheme for laboratory investigation of adult acne. Although most adult acne patients show no signs of clinical or laboratory hyperandrogenism, slightly elevated levels of S-DHEA have been observed. DHT could be useful as a primary marker of peripheral androgen production. A distal metabolite of DHT, produced in androgen-responsive tissues, is 3-alpha, 17-beta-androstanediol glucuronate. This metabolite can be used as a marker of hyperandrogenism, especially in women with idiopathic hirsutism.

Figure 1

Laboratory investigations of Adult Acne

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ba25b7c0-e720-413c-8335-c0e6bb334fdeimage1.png

Treatment

Adult acne is a therapeutic challenge because it presents a tendency to relapse, even after cycles of oral antibiotics or isotretinoin. The typical evolution of adult acne, with frequent relapses, makes maintenance treatment essential.8 According to panel members numerous factors should be considered while managing a patient of adult acne such as its severity, response to previous treatments, psychosocial impact, possibility of pregnancy, slow response to treatment and increased risk of sensitive skin irritation. Individual preferences and costs should also be considered.

According to experts’ topical therapies are recommended in management of mild to moderate grades of acne and during maintenance therapy. Topical retinoids or combination of topical retinoids plus benzoyl peroxide (BPO) is recommended in both males and non-pregnant female patients with mild grade of adult acne. Experts recommended use of topical or systemic antibiotics and/or hormonal therapies along with topical retinoids and BPO in patients with moderate grades of adult acne. Patients with severe grade of acne should be treated with oral isotretinoin. In patients not responding to oral isotretinoin systemic antibiotics and/or hormonal therapies are recommended.

In pregnant, lactating females or females who are planning pregnancy topical azelaic acid 20% is recommended.

Figure 2

Represents the management algorithm for adult acne.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ba25b7c0-e720-413c-8335-c0e6bb334fdeimage2.png

Retinoids

Adapalene and tretinoin are most commonly used topical retinoids in India. Both the drugs have proven efficacy and safety in management of acne.

Adapalene

Multiple clinical studies have established the efficacy and safety of adapalene in patients with adult acne. Berson D et al in their study in patients with adult acne reported that adapalene was associated with significant improvement in both inflammatory lesions (–61%) and non-inflammatory lesions (– 51%) after 12 weeks of treatment with adapalene compared to vehicles (P = 0.045). 9 Thielitz A et al. reported similar results with 0.1% adapalene with good tolerance. 10 Considering the relative better safety profile of adapalene especially adapalene with microsphere technology, experts commented that adapalene should be considered in all patients with mild acne and as maintenance therapy.

Tretinoin

According to experts, tretinoin is good alternative to adapalene in patients with adult acne. Berger R et al. in their study reported that microsphere tretinoin in concentration range of 0.04% to 0.1% is associated with significant improvement in inflammatory acne in adolescents and adults. 11

Topical Antibiotics

Antibiotics plays very important role in management of acne. Because of their direct anti-inflammatory activity and inhibitory action of P. acnes topical antibiotics have very good efficacy in patients with acne. However, considering the increase in prevalence of resistance to antibiotic 12 experts recommended that topical antibiotic should never be used as monotherapy.

Benzoyl peroxide (BPO)

According to experts because of its multimodal mechanism of action and synergistic activity with other topical antiacne medications BPO in combination with retinoids or topical antibiotics is useful in management of patients with mild to moderate grades of adult acne. According to experts BPO above 5% are not recommended for use in adults especially in females because of increased risk of contact irritant dermatitis. 12

Retinoids + Benzoyl peroxide

Combination of topical retinoids with BPO have synergistic activity which is associated with rapid onset of action and significant reduction in lesion within first week. 13 Gold LS et al in their meta-analysis concluded that combination therapy with adapalene 0.1% and 2.5% benzoyl peroxide gel is associated with significant improvement in acne lesions compared to the vehicle in women 25 years of age or older. 13 Considering these facts, experts recommended that the combination should be considered as first line therapy in management of adult patients with mild acne.

Antibiotics + Benzoyl peroxide

According to experts BPO reduces the development of antibiotic resistance, hence combination of BPO along with topical antibiotics can be considered in patients with adult acne especially with pustular acne. Kircik LH et al in their study in 20 patients with adult acne reported that the combination of BPO and clindamycin is associated with 70% and 58% decrease in inflammatory and non-inflammatory lesion after 12 weeks of therapy. On further continuation of therapy for 24 weeks the improvement was 93% and 90%, respectively. There were no serious adverse events. Based on these results authors concluded that the combination of clindamycin and BPO can be used as initial as well as maintenance therapy in management of acne. 14 Experts were also of same opinion.

Azelaic acid

According to experts, comparable efficacy, favourable tolerability profile and high rates of satisfaction compared to other topical therapies in patients with mild to moderate acne makes azelaic acid promising alternative in management of patients with adult acne. Various clinical studies have established the efficacy and safety of azelaic acid in management of adult acne. Kainz JT et al concluded that topical azelaic 20% treatment significantly improved the quality of life of patients and reduced the severity of acne in adult patients. 15 In a study by Kircik LH et al, azelaic acid 15% gel, was associated with significant reduction in acne and post-inflammatory pigmentation. 16 Rocha MAD et al reported similar results in their study with azelaic acid 15%. 17 Azelaic acid is pregnancy category B drug, hence according to experts azelaic acid can be considered as first line therapy in pregnant and breastfeeding females.

Systemic Antibiotics

Systemic antibiotics are first choice drugs in management of patients with moderate to severe acne. The combination of systemic antibiotics with topical antiacne medications have synergistic activity, faster onset of action and shorter duration of therapy. 18 Tetracycline and its derivatives are the first choice of antibiotics for the treatment of adult acne.

However, considering the scenario of antibiotic resistance in India, experts commented that, systemic antibiotics should not be used as monotherapy in the treatment of acne. 18, 19, 20 As mentioned earlier, BPO in the concentration of 2.5 to 5% should be considered in combination with systemic antibiotics because of synergistic action, faster response and avoidance of development of resistance. 21 Azelaic acid as well as topical retinoids are alternatives. 22

Hormonal Therapies

Hormonal therapies are one of the most important treatment modalities in management of patients with adult acne especially in female patients. Because of their slow onset of action, hormonal therapies should always be used in combination with other antiacne therapies. Hormonal therapies are recommended even in patients with normal hormonal profile. Since hormonal agents are not associated with bacterial resistance and comparable safety profile, they represent very promising alternative to systemic antibiotics for long term therapy. 18, 22, 23

According to experts, hormonal agents should be considered when patients is having severe seborrhoea, premenstrual worsening of symptoms, recalcitrant inflammatory acne despite repeated cycles of isotretinoin and in situations where contraception is required.

Androgen receptor blockers

Androgen receptor have been commonly used in management of patients with adult female acne. Commonly used agents are cyproterone acetate, spironolactone, drospirenone and flutamide. 22, 23

  1. Cyproterone Acetate: It acts by blocking androgen receptors. It is often used in combination with estrogens in the OCP, with ethinyl estradiol (EE) 35 ug. When used as monotherapy, it is given from day 1 to 10 of the menstrual cycle. Menstrual abnormalities, breast tenderness, nausea, vomiting, fluid retention, leg edema and headache common adverse events. 24, 25

  2. Spironolactone: According to experts, spironolactone is specifically useful in patients with polycystic ovarian disease. Sato et al in their study demonstrated that spironolactone 200mg/day was associated with significant improvement in acne in females and it is good option for severe, recurring, and widespread acne. 26 Plovanich M et al in their retrospective study found that there spironolactone is associated with good safety profile and potassium monitoring is not required in healthy females with acne. 27 Lessner E et al demonstrated that the combination therapy with spironolactone and topical retinoids provide a superior response compared to topical retinoids alone in adult females with acne. 28

Oral Contraceptive Pills

As per American Academy of Dermatologists and Global acne alliance, oral contraceptives (OCs) consisting of both estrogen and progestin should be considered as first choice therapies in management of female patients with acne. These agents are as effective as oral antibiotics in reducing acne lesions at 6 months of treatment. 18, 29, 30, 31

According to experts, while prescribing OCs, proper counselling of patients regarding risks and benefits to oral contraceptive therapies should be done.

Common combinations used:

  1. CPA 2 mg + EE 0.035 mg

  2. Drospirenone 3 mg + Ethinyl estradiol 0.03 mg

  3. Desogestrel 0.15 mg + Ethinyl Estradiol 0.03 mg

  4. Desogestrel 0.15 mg + Ethinyl Estradiol 0.02 mg

Started on day 1 of menstrual cycle (if contraception is required) or day 5 (if date of menstruation is to be maintained).23

Insulin-sensitizing agents Metformin and thiazolidinediones (rosiglitazone/pioglitazone).

These agents act by improving insulin sensitivity, and subsequently, decrease circulating androgen levels. In addition, these agents have a role in the treatment of PCOD. Metformin is given in a dose of 500 mg- 2000mg/day. Its side effects are diarrhea, nausea, taste changes, and lactic acidosis. 23

Isotretinoin

Isotretinoin is associated with unique and multimodal mechanism of action which includes reduction in size and activity of sebaceous glands, anti-inflammatory activity because of modulation of TLR 2 expression and gene transcription mediated by Fox O. 32, 33 Hence oral isotretinoin is recommended as first line therapy in patients with severe acne and in patients with no response to other antiacne therapies. 18 Because of increased risk of teratogenicity, isotretinoin should be used very cautiously in females of reproductive age group. According to experts, proper counselling of patients regarding teratogenicity and requirement of highly effective contraceptive method is very important.

The recommended daily dose is 0.5 to 1.0mg / kg, after meals, for a period of 6 to 12 months. 34 Multiple studies have evaluated the low dose regimes of isotretinoin in adult patients with acne. Boyraz N et al have demonstrated that both intermittent and continuous low-dose isotretinoin regimens are very well tolerated and effective as classical regimens in the treatment of moderate acne vulgaris. 35 Rademaker M et al evaluated the significant improvement in low grade adult acne with 5mg/day dose of isotretinoin.36 Dhaked DR et al in their study concluded that isotretinoin 20mg given either daily or on alternate day was equally effective in adult patients with moderate to severe acne.37

According to experts, low dose isotretinoin regimens may be a useful option for adult acne resistant to topical and hormonal treatments because of reduced risk of adverse events. However, there is increased risk of relapse with low dose regimes of isotretinoin especially in patients with severe acne.

Adjuvant treatments

Cosmetic use

According to experts, cleansers and moisturizers are very important component of any therapeutic regimen for patient with adult acne especially in females. Use of cleansers and moisturizers is associated with improved patient adherence to therapy thus increasing the treatment outcomes. Experts commented that aqueous non-comedogenic moisturisers containing minimal allergenic ingredients should be preferred.

Experts advised that sunscreens are very important adjuvants in patients with acne and should be recommended in all patients especially in patient who are increased risk of developing post inflammatory hyperpigmentation. According to experts, all skin care products and cosmetics should be anti-comedonal and oil free. 38, 39

Niacinamide

Niacinamide is useful adjuvant in management of acne because of its multiple effects like antimicrobial activity, sebostatic property and anti-inflammatory effects. It is also useful in management of post inflammatory hyperpigmentation since it inhibits melanosome transfer.40

Light therapy

Lasers, blue light and blue– red light, intensed pulsed light, pulsed dye lasers and photodynamic therapy (PDT), used with or without photosensitising agents are useful in some patients with adult acne. 41, 42 As per available evidence, light therapy should be best used as an adjuvant therapy along with standard therapy in management of patients with adult acne. 18 Because of their shorter duration patients may show better adherence to light therapies, however their long term safety and efficacy is not established.42, 43 Amongst the light therapies PDT provides the most consistent outcomes on inflammatory acne.42, 44 Ablative and non-ablative laser therapy can also be used to treat acne scarring.45

Chemical peels

According to experts, chemical peels can be sued as an adjunctive therapy or as maintenance therapy in patients with adult acne. Some of the common chemical peels which are recommended in patients with adult acne are, glycolic acid (30, 35, 50 or 70%), salicylic acid (20–30%) and Jessner’s solution.46, 47

Mechanical procedures

Similar to other adjuvant modalities experts recommended that mechanical procedures such as comedone extraction, cautery, dermabrasion, etc can be useful in certain patients with adult acne. Comedone extraction at the time of ovulation may be associated with reduction in inflammatory lesions.48 Dermabrasion is effective in patients with atrophic acne scars 49 and can also be combined with chemical peels. 50

Maintenance therapy

Acne is associated with increased likelihood of relapse even after prolonged treatment, hence according to experts, maintenance therapy is very important in patients with adult acne. As per experts recommends topical retinoids such as adapalene or tretinoin should be considered as first choice drugs as maintenance therapy. In females of reproductive age group azelaic acid 15 or 20% is good alternative. Experts commented that topical or systemic antibiotics should never be used as maintenance therapy.

Recommendations for therapy in special patient populations

Patients who wish to become pregnant

Because of their relative safety during pregnancy, experts recommended that topical azelaic acid (15 or 20%) or BPO (2.5–5%) monotherapy should be considered as first choice therapy in such patients is recommended. Combination of BPO along with other antibiotic such as erythromycin or clindamycin can also be considered in patients with severe inflammatory acne. In patients who are not responding to topical antibiotics systemic erythromycin or clindamycin can be considered based on risk benefit ratio. In patients with nodulocystic acne, topical corticosteroids or a short course of systemic corticosteroids can be considered. Light treatment and superficial chemical peels are recommended as adjunctive therapy.

Patients who are pregnant or breastfeeding

Azelaic acid is pregnancy category B drug. Even though there are no adequate and well-controlled studies in pregnant women for azelaic acid no harmful teratogenic effects were reported with topical azelaic acid (15 – 20%). 18, 22 Considering these facts, experts commented that in pregnant and breast-feeding females azelaic acid should be considered as first choice drug.

In pregnant females with acne who are not responding to topical therapies systemic glucocorticoids or antibiotics (erythromycin or clindamycin) can be considered after the first trimester of pregnancy. Light treatment, mechanical procedures and chemical peels are recommended as adjunctive therapy, and skin care products and cosmetics may also be used.

Conclusion

Incidence of adult acne is on the rise and it have significant negative impact on quality of life of patients. Patients with adult acne requires different treatment approach compared to adolescent acne. A holistic treatment regimen which combines standard therapy along with adjuvant therapies are recommended in adult patients. In patients with adult acne, it is very important to individualized the treatment considering the specific characteristics and need of the patients. Patient education on factors including correct application of topical therapy, potential side-effects, likely time to clinical improvement and expected outcomes is important in encouraging adherence with therapy.

Acknowledgement

Authors would like to thank Glenmark pharmaceuticals for scientific and logistic support for conduct of meeting and preparation of manuscript.

Disclaimer

This consensus reflects the best available evidence at the time of preparation. Adherence to this consensus may not ensure successful treatment in every situation. The treating physician must make the ultimate judgment regarding the choice of any specific therapy in the context of circumstances for individual case scenarios.

Source of Funding

No financial support was received for the work within this manuscript.

Conflicts of Interest

There are no conflicts of interest.

References

1 

JK Tan K Bhate A global perspective on the epidemiology of acneBr J Dermatol2015172131210.1111/bjd.13462

2 

JL Burton WJ Cunliffe L Stafford The prevalence of acne vulgaris in adolescenceBr J Dermatol19718521192610.1111/j.1365-2133.1971.tb07195.x

3 

MA Rocha E Bagatin Adult-onset acne: prevalence, impact, and management challengesClin Cosmet Investig Dermatol201811596910.2147/ccid.s137794

4 

CN Collier JC Harper JA Cafardi The prevalence of acne in adults 20 years and olderJ Am Acad Dermatol2008581569

5 

AC Perkins J Maglione GG Hillebrand K Miyamoto AB Kimball Acne Vulgaris in Women: Prevalence Across the Life SpanJ Women's Health20122122233010.1089/jwh.2010.2722

6 

F Poli B Dreno M Verschoore An epidemiological study of acne in female adults: results of a survey conducted in FranceJ Eur Acad Dermatol Venereol2001156541510.1046/j.1468-3083.2001.00357.x

7 

V Goulden GI Stables WJ Cunliffe Prevalence of facial acne in adultsJ Am Acad Dermatol199941457780

8 

R. Holzmann K. Shakery Postadolescent Acne in FemalesSkin Pharmacol Physiol201427s13810.1159/000354887

9 

D Berson Alexis A Adapalene 0.3% for the Treatment of Acne in WomenJ Clin Aesthet Dermatol20136325

10 

A. Thielitz A. Lux A. Wiede S. Kropf E. Papakonstantinou H. Gollnick A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acneJ Eur Acad Dermatol Venereol20152947899610.1111/jdv.12823

11 

R Berger R Rizer A Barba D Wilson D Stewart R Grossman Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: A 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trialClin Ther200729610869710.1016/j.clinthera.2007.06.021

12 

B. Dréno A. Layton C.C. Zouboulis J.L. López-Estebaranz A. Zalewska-Janowska E. Bagatin Adult female acne: a new paradigmJ Eur Acad Dermatol Venereol201327910637010.1111/jdv.12061

13 

L S Gold H Baldwin M J Rueda N Kerrouche B Dréno Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged FemalesJ Clin Aesthet Dermatol20169239

14 

L H Kircik Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel: Long-Term Use in Adult Females With Moderate Acne VulgarisJ Drugs Dermatol2017165436

15 

JT Kainz G Berghammer P Auer-Grumbach V Lackner S Perl-Convalexius R Popa Azelaic acid 20 % cream: effects on quality of life and disease severity in adult female acne patientsJ Dtsch Dermatol Ges2016141212495910.1111/ddg.12889

16 

L H Kircik Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled studyJ Drugs Dermatol20111058690

17 

MAD Rocha LRS Guadanhim A Sanudo E Bagatin Modulation of Toll Like Receptor-2 on sebaceous gland by the treatment of adult female acneDermato-Endocrinology201791e136157010.1080/19381980.2017.1361570

18 

D M Thiboutot B Dréno A Abanmi A F Alexis E Araviiskaia M I Barona Cabal M I Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in AcneJ Am Acad Dermatol2018782123

19 

H.P. Gollnick V. Bettoli J. Lambert E. Araviiskaia I. Binic C. Dessinioti A consensus-based practical and daily guide for the treatment of acne patientsJ Eur Acad Dermatol Venereol201630914809010.1111/jdv.13675

20 

B Dreno D Thiboutot H Gollnick V Bettoli S Kang JJ Leyden Antibiotic stewardship in dermatology: limiting antibiotic use in acneEur J Dermatol2014243330410.1684/ejd.2014.2309

21 

D Thiboutot B Dreno H Gollnick V Bettoli S Kang J J Leyden A call to limit antibiotic use in acneJ Drugs Dermatol: JDD20131213313

22 

E Bagatin THP de Freitas MC Rivitti-Machado BM Ribeiro S Nunes MAD da Rocha Adult female acne: a guide to clinical practiceAn Bras Dermatol2019941627510.1590/abd1806-4841.20198203

23 

S Kaur P Verma A Sangwan S Dayal V Jain Etiopathogenesis and therapeutic approach to adult onset acneIndian J Dermatol2016614403710.4103/0019-5154.185703

24 

C Lakshmi Hormone therapy in acneIndian J Dermatol Venereol Leprol20137932237

25 

T L Ebede E L Arch D Berson Hormonal treatment of acne in womenJ Clin Aesthet Dermatol200921622

26 

K Sato D Matsumoto F Iizuka E Aiba-Kojima A Watanabe-Ono H Suga Anti-androgenic Therapy Using Oral Spironolactone for Acne Vulgaris in AsiansAesthetic Plast Surg20063066899410.1007/s00266-006-0081-0

27 

M Plovanich QY Weng A Mostaghimi Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for AcneJAMA Dermatol20151519941410.1001/jamadermatol.2015.34

28 

E Lessner S Fisher K Kobraei M Osleber R Lessner L Elliott Spironolactone and topical retinoids in adult female cyclical acneJ Drugs Dermatol2014131269

29 

AL Zaenglein AL Pathy BJ Schlosser A Alikhan HE Baldwin DS Berson Guidelines of care for the management of acne vulgarisJ Am Acad Dermatol20167459457310.1016/j.jaad.2015.12.037

30 

A O Arowojolu M F Gallo L M Lopez D A Grimes Combined oral contraceptive pills for treatment of acneCochrane Database Syst Rev201244254425

31 

EB Koo TD Petersen AB Kimball Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgarisJ Am Acad Dermatol2014713450910.1016/j.jaad.2014.03.051

32 

MC Dispenza EB Wolpert KL Gilliland JP Dai Z Cong AM Nelson Systemic Isotretinoin Therapy Normalizes Exaggerated TLR-2-Mediated Innate Immune Responses in Acne PatientsJ Invest Dermatol20121329219820510.1038/jid.2012.111

33 

B C Melnik Isotretinoin and FoxO1: A scientific hypothesisDermatoendocrinol2011314165

34 

AM Layton WJ Cunliffe Guidelines for optimal use of isotretinoin in acneJ Am Acad Dermatol1992276S2S710.1016/s0190-9622(08)80252-6

35 

N Boyraz PK Mustak Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgarisInt J Dermatol2013521265710.1111/j.1365-4632.2012.05853.x

36 

M. Rademaker J.M. Wishart N.M. Birchall Isotretinoin 5 mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind studyJ Eur Acad Dermatol Venereol20142867475410.1111/jdv.12170

37 

DR Dhaked RS Meena A Maheshwari US Agarwal S Purohit A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgarisIndian Dermatol Online J2016753788510.4103/2229-5178.190505

38 

L Chularojanamontri P Tuchinda K Kulthanan K Pongparit Moisturizers for acnewhat are their constituentsJ Clin Aesthet Dermatol201473644

39 

E. Araviiskaia B. Dréno The role of topical dermocosmetics in acne vulgarisJ Eur Acad Dermatol Venereol20163069263510.1111/jdv.13579

40 

J Wohlrab D Kreft Niacinamide - Mechanisms of Action and Its Topical Use in DermatologySkin Pharmacol Physiol2014276311510.1159/000359974

41 

M Tsoukas KA Adya AC Inamadar S Pei Light-based therapies in acne treatmentIndian Dermatol Online J2015631455710.4103/2229-5178.156379

42 

B. Dréno A. Layton C.C. Zouboulis J.L. López-Estebaranz A. Zalewska-Janowska E. Bagatin Adult female acne: a new paradigmJ Eur Acad Dermatol Venereol201327910637010.1111/jdv.12061

43 

F.L. Hamilton J. Car C. Lyons M. Car A. Layton A. Majeed Laser and other light therapies for the treatment of acne vulgaris: systematic reviewBr J Dermatol 2009160612738510.1111/j.1365-2133.2009.09047.x

44 

M Hædersdal K Togsverd-Bo HC Wulf Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgarisJ Eur Acad Dermatol Venereol 20082232677810.1111/j.1468-3083.2007.02503.x

45 

MWS Ong SJ Bashir Fractional laser resurfacing for acne scars: a reviewBr J Dermatol 201216661160910.1111/j.1365-2133.2012.10870.x

46 

B Dréno TC Fischer E Perosino F Poli MS Viera MI Rendon Expert Opinion: Efficacy of superficial chemical peels in active acne management - what can we learn from the literature today? Evidence-based recommendationsJ Eur Acad Dermatol Venereol 201125669570410.1111/j.1468-3083.2010.03852.x

47 

E Kessler K Flanagan C Chia Comparison of alpha- and betahydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgarisDermatol Surg2008344550

48 

K. Steventon Expert opinion and review article: The timing of comedone extraction in the treatment of premenstrual acne - a proposed therapeutic approachInt J Cosmet Sci 20113329910410.1111/j.1468-2494.2010.00610.x

49 

E Bagatin LR Santos Guadanhim S Yarak CS Leão Kamamoto FA de Almeida Dermabrasion for Acne Scars During Treatment with Oral IsotretinoinDermatol Surg2010364483910.1111/j.1524-4725.2010.01474.x

50 

S Ayhan C N Baran R Yavuzer Combined chemical peeling and dermabrasion for deep acne and posttraumatic scars as well as aging facePlast Reconstr Surg1998102123846



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 10-05-2021

Accepted : 17-05-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijced.2021.019


Article Metrics






Article Access statistics

Viewed: 1860

PDF Downloaded: 795